Dizhe Pharmaceutical (688192.SH) issued an expected loss. The net loss for half a year is estimated to be around 210 million yuan

According to Zhitong Finance App News, Dizhe Pharmaceutical (688192.SH) released its 2026 semi-annual performance forecast. The company expects a net loss of about 210 million yuan attributable to the owner of the parent company for the 2026 half year, a decrease of about 44.35% over the previous year. The net loss attributable to the owner of the parent company after deducting non-recurring profit and loss for the first half year of 2026 is estimated to be about 231 million yuan, a year-on-year decrease of about 44.90%.

During the reporting period, the company's two approved products, Schwarzhe ^{® (generic name: sulvoritinib tablets) and Collixitinib®} (generic name: golisitinib capsules), supported and covered by national health insurance policies, continued to improve patient accessibility with outstanding differentiated clinical advantages, and the product market share continued to expand, driving the company's business performance to continue to improve. It is expected to achieve revenue of around 522 million yuan in the first half of ²⁰²⁶. The company's revenue increased dramatically in the first half of 2026. At the same time, product development is progressing smoothly, and R&D investment remains at a high level. It is expected that net profit attributable to owners of the parent company will continue to be negative in the first half of 2026, but there have been no major adverse changes in the company's main business or core competitiveness.